IRBs seeking more money for clinicals
This article was originally published in The Gray Sheet
Institutional review board fees of $1,500-$2,000 are becoming increasingly prevalent in clinical agreements, according to Thoratec VP-Regulatory Affairs Donald Middlebrook. When budgeting for trials, "I used to set aside...for the few centers [that required] the charges. Now it's almost standard," the exec told IIR's Clinical Trial Strategies for Medical Devices & Diagnostics conference Sept. 30 in Washington, D.C...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.